/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering messenger RNA (mRNA) therapeutics and vaccines to transform the future of medicine. With a market cap of $15.9 billion, Moderna offers a diverse portfolio of mRNA-based vaccines and treatments across infectious diseases, immuno-oncology, and rare diseases. The company is set to announce its Q4 earnings on Thursday, Feb. 27.
Ahead of the event, analysts expect Moderna to report a loss of $2.94 per share, down 634.6% from the profit of $0.55 per share in the same quarter last year. The company has consistently surpassed Wall Street’s EPS estimates in each of its last four quarterly reports.